# A Study of DM001 in Patients With Advanced Solid Tumors

> **NCT06475937** · PHASE1 · RECRUITING · sponsor: **Xadcera Biopharmaceutical (Suzhou) Co., Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Solid Carcinoma

## Interventions

- **DRUG:** DM001

## Key facts

- **NCT ID:** NCT06475937
- **Lead sponsor:** Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2026-08-13
- **Final completion:** 2027-02-13
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475937, "A Study of DM001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06475937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*